Solana Rapaport

Dr. Solana Rapaport

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
SRSolana Rapaport
Solana Rapaport
MMMariana Maurino
Mariana Maurino
MMMaria Alejandra Morales
Maria Alejandra Morales
CFCintia Fabbri
Cintia Fabbri
VLVictoria Luppo
Victoria Luppo
AUAnalia Urueña
Analia Urueña
Background: Dengue is an important public health problem in Argentina, as in many other countries. We reviewed and updated information on the dengue disease burden in Argentina over a 10-year period. Methods: We conducted a retrospective descriptive study from 2010 to 2020 based on data from the National Health Surveillance System. The main outcomes included dengue cases, incidence rates, deaths, and serotype distribution by season, age group, and region. Results: A total of 109,998 confirmed cases of dengue were reported. Seasonality stands out, prevailing during summer and autumn. Two main outbreaks (seasons 2015/16 and 2019/20), with increasing magnitude, were observed. The 2019/20 season showed the highest number of cases (58,731) and incidence rate (135/100,000). The Northeast region had the highest number of cases and incidence rate. In 2020, for the first time, autochthonous cases were registered in the Cuyo region. The only region with no autochthonous cases was the South. Adolescents and young adults showed the highest incidence rate. The case fatality rate for the period was 0.05%. Four serotypes circulated, but the predominant one was DEN-1 (78%). Conclusions: Dengue has been expanding temporally and spatially. Although the DEN-1 serotype widely predominated, the increasing circulation of other serotypes raises concerns regarding re-exposure and the severity of future cases. Understanding epidemiological trends is key to defining public prevention and control policies.

18 September 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
RDRoberto Debbag
Roberto Debbag
María L. Ávila-AgueroMaría L. Ávila-Aguero
María L. Ávila-Aguero
JBJosé Brea
José Brea
RKRenato Kfouri
Renato Kfouri
FMFlor M. Muñoz
Flor M. Muñoz
Alfonso J. Rodriguez-MoralesAlfonso J. Rodriguez-Morales
Alfonso J. Rodriguez-Morales
Respiratory syncytial virus (RSV) remains a leading cause of infant lower respiratory tract infection, hospitalization, and death in Latin America and the Caribbean, where unequal access to diagnosis, medical care, oxygen, referral, and intensive care worsens outcomes. New passive immunization tools, maternal RSV prefusion F vaccination and long-acting monoclonal antibodies, can protect infants before peak vulnerability. Still, their population impact depends on timing, coverage, equity, financing, surveillance, and program design. Emerging regional experience with hybrid strategies may help close protection gaps among infants missed or insufficiently protected by maternal immunization. Severe early-life RSV disease is consistently associated with recurrent lower respiratory tract infections, wheezing, asthma, impaired lung-function trajectories, and increased health-care use. However, causality and long-term effects of current preventive products remain uncertain. A regional agenda linking maternal-infant cohorts, surveillance, equity analyses, and life-course economic evaluation is needed to define the full public health value of RSV prevention.